LUMOS PHARMA INC. - C

Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD

28 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023

15 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023

03 Jan 2023 09:00:00 By Nasdaq GlobeNewswire

KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients

12 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

29 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference

22 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates

14 Nov 2022 06:10:00 By Nasdaq GlobeNewswire

Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency

14 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference

26 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

31 Aug 2022 09:00:00 By Nasdaq GlobeNewswire

Lumos Pharma Announces Share Repurchase Program

16 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates

09 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022

27 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in Upcoming Investor Conferences

16 May 2022 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

10 May 2022 16:01:01 By Nasdaq GlobeNewswire

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

05 May 2022 09:00:01 By Nasdaq GlobeNewswire

Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022

26 Apr 2022 09:00:03 By Nasdaq GlobeNewswire

Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD

11 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in the Cantor Rare Disease Symposium

23 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials

10 Mar 2022 16:01:00 By Nasdaq GlobeNewswire